Sign In
Buy BCAB
$3.29
-0.0900 (-2.66%)
At Close: Jul 31, 2026
BioAtla to Participate in the Jefferies London Healthcare Conference
04:05pm, Monday, 06'th Nov 2023
SAN DIEGO, Nov. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
SAN DIEGO, Oct. 10, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
BioAtla to Participate in the H.C. Wainwright 25th Annual Global Investment Conference
08:00am, Wednesday, 06'th Sep 2023
SAN DIEGO, Sept. 06, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody the
BioAtla to Participate in Upcoming Investor Conferences in August
04:01pm, Thursday, 03'rd Aug 2023
SAN DIEGO, Aug. 03, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
BioAtla, Inc. (BCAB) Q2 2023 Earnings Call Transcript
11:18pm, Tuesday, 01'st Aug 2023
BioAtla, Inc. (NASDAQ:BCAB ) Q2 2023 Earnings Conference Call August 1, 2023 4:30 PM ET Company Participants Bruce Mackle - IR, LifeSci Advisors, LLC Jay Short - Chairman & Chief Medical Officer Richa
BioAtla to Announce Second Quarter 2023 Financial Results and Provide Business Highlights on August 1, 2023
08:00am, Tuesday, 25'th Jul 2023
SAN DIEGO, July 25, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
BioAtla, Inc. (BCAB) Q1 2023 Earnings Call Transcript
10:51pm, Thursday, 11'th May 2023
BioAtla, Inc. (NASDAQ:BCAB ) Q1 2023 Earnings Conference Call May 11, 2023 4:30 PM ET Company Participants Bruce Mackle - IR, LifeSci Advisors, LLC Jay Short - Chairman and CEO Richard Waldron - CFO P
BioAtla to Announce First Quarter 2023 Financial Results and Provide Business Highlights on May 11, 2023
08:00am, Thursday, 04'th May 2023
SAN DIEGO, May 04, 2023 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody thera
BioAtla, Inc. (BCAB) Q4 2022 Earnings Call Transcript
10:33pm, Thursday, 23'rd Mar 2023
BioAtla, Inc. (NASDAQ:BCAB ) Q4 2022 Earnings Call Transcript March 23, 2023 4:30 PM ET Company Participants Bruce Mackle - Investor Relations, LifeSci Advisors, LLC Jay Short - Chairman, Chief Execut
7 Cheap But Risky Biotech Stocks
01:58pm, Wednesday, 18'th Jan 2023
Biotech stocks remain depressed, nearly two years into a dip that has seen the SPDR S&P Biotech ETF drop nearly 50%.
Can BioAtla, Inc. (BCAB) Climb 260% to Reach the Level Wall Street Analysts Expect?
11:18am, Tuesday, 15'th Nov 2022
The mean of analysts' price targets for BioAtla, Inc. (BCAB) points to a 259.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among a
BioAtla, Inc. (BCAB) Q3 2022 Earnings Call Transcript
11:47am, Sunday, 06'th Nov 2022
BioAtla, Inc. (NASDAQ:BCAB ) Q3 2022 Earnings Conference Call November 3, 2022 4:30 PM ET Company Participants Bruce Mackle - Investor Relations Jay Short - Chairman, Chief Executive Officer and Co-Fo
BioAtla, Inc. (BCAB) Reports Q3 Loss, Lags Revenue Estimates
12:48pm, Friday, 04'th Nov 2022
BioAtla, Inc. (BCAB) delivered earnings and revenue surprises of 10.39% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?
BioAtla to Announce Third Quarter 2022 Financial Results and Provide Business Highlights on November 3, 2022
08:00am, Thursday, 27'th Oct 2022
SAN DIEGO, Oct. 27, 2022 (GLOBE NEWSWIRE) -- BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody ther
BioAtla: Back From The Dead
04:12pm, Friday, 23'rd Sep 2022
Shares of conditionally active biologics concern BioAtla, Inc. are beginning to rebound from a 97% plunge as encouraging data from two candidates has sparked the turnaround. BioAtla leverages its expe
